



Response #10
4.16.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re PATENT APPLICATION OF

Grillo-Lopez, et al.

Group Art Unit: 1642

Application Serial No. 09/762,587

Examiner: M. Davis

Filed: September 6, 2001

Title: COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING
ADMINISTRATION OF ANTI-CD20 ANTIBODY

SUPPLEMENTAL RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the office action [election of species requirement], mailed March 25, 2003, applicants elect with traverse the species of intermediate grade NHL. The traversal is on the basis that the different grades of NHL represent different degrees of progression of a single disease, and therefore a concurrent search of all NHL grades would not impose a significant burden.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Thomas A. Cawley, Jr., Ph.D.
Registration No. 40,944

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2144 Direct Dial
(703) 905-2500 Facsimile

Date: April 14, 2003